China Pharma Holdings, Inc.: Form 10-Q for the period ended Sep 30, 2018
Filed with the SEC on Nov 14, 2018 and accepted by EDGAR at Nov 14, 2018, 16:08 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2018-09-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2018-07-01 to 2018-09-30 | $2.3m | us-gaap:Revenues |
| Revenue | 9 months2018-01-01 to 2018-09-30 | $9.1m | us-gaap:Revenues |
| Cost of revenue | 3 months2018-07-01 to 2018-09-30 | $1.8m | us-gaap:CostOfRevenue |
| Cost of revenue | 9 months2018-01-01 to 2018-09-30 | $6.9m | us-gaap:CostOfRevenue |
| Gross profit | 3 months2018-07-01 to 2018-09-30 | $512.5k | us-gaap:GrossProfit |
| Gross profit | 9 months2018-01-01 to 2018-09-30 | $2.1m | us-gaap:GrossProfit |
| Research and development | 3 months2018-07-01 to 2018-09-30 | $62.1k | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months2018-01-01 to 2018-09-30 | $107.9k | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2018-07-01 to 2018-09-30 | −$1.9m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2018-01-01 to 2018-09-30 | −$2.9m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2018-07-01 to 2018-09-30 | $101.7k | us-gaap:InterestExpense |
| Interest expense | 9 months2018-01-01 to 2018-09-30 | $361.4k | us-gaap:InterestExpense |
| Income tax | 3 months2018-07-01 to 2018-09-30 | −$160.5k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months2018-01-01 to 2018-09-30 | −$111.9k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2018-07-01 to 2018-09-30 | −$1.9m | us-gaap:NetIncomeLoss |
| Net income | 9 months2018-01-01 to 2018-09-30 | −$3.2m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2018-07-01 to 2018-09-30 | −$0.04 | us-gaap:EarningsPerShareBasicAndDiluted |
| Diluted EPS | 9 months2018-01-01 to 2018-09-30 | −$0.07 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 9 months2018-01-01 to 2018-09-30 | $1.0m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months2018-01-01 to 2018-09-30 | $33.3k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2018-09-30 | $667.6k | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2018-09-30 | $9.7m | us-gaap:AssetsCurrent |
| Total assets | At period end2018-09-30 | $52.5m | us-gaap:Assets |
| Current liabilities | At period end2018-09-30 | $9.8m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2018-09-30 | $14.9m | us-gaap:Liabilities |
| Long-term debt | At period end2018-09-30 | $6.6m | us-gaap:LongTermDebt |
| Shareholders' equity | At period end2018-09-30 | $37.6m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001213900-18-015783. Last ingested by Listed: Oct 30, 2026, 16:51 ET. Listed shows no prices and gives no investment advice.